

Charity number: 1166985

THE LIVER GROUP CHARITY CIO

UNAUDITED ANNUAL REPORT AND
ACCOUNTS

YEAR ENDED 31 DECEMBER 2024



THE LIVER GROUP CHARITY CIO

CONTENTS

	Page
Reference and Administrative Details of the Charity, its Trustees and Advisers	1
Trustees' Report	2 - 5
Chairman's Statement	6
Statement of Financial Activities	7
Balance Sheet	8
Notes to the Financial Statements	9 - 16
The following pages do not form part of the statutory financial statements:	
Donations to the 'Liver for Life' appeal	17
Scientific publications and presentations	18

THE LIVER GROUP CHARITY CIO

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2024

Trustees	Dr David Holbrook (Chairman) Mary Collier Susan Eggleton Dr Martin Giles
Charity registered number	1166985
Principal office	C/O Institute for Liver and Digestive Health Royal Free Hospital Campus - University College Medical School Rowland Hill Street Hampstead NW3 2PF
Patrons	Prof Sir Roger Penrose OM FRS Kay Glendinning MBE

THE LIVER GROUP CHARITY CIO

TRUSTEES' REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees present the annual report together with the financial statements of The Liver Group Charity CIO for the year ended 31 December 2024. The Trustees confirm that the Annual Report and financial statements of the Charity comply with the current statutory requirements, the requirements of the Charity's governing document and provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Reference and administrative details

The Liver Group Charity CIO ("the Charity") is registered with the Charity Commission of England and Wales, under registration number 1166985. The Charity was registered on 6 May 2016 as a Charitable Incorporated Organisation, and as at 30 September 2016 took over the activities and assets of The Liver Group (registered charity number 1024533) which has subsequently been closed. The principal operating address is UCL Institute for Liver and Digestive Health, UCL - Royal Free Hospital Campus, University College Medical School, Upper Third Floor, Rowland Hill St, Hampstead, London NW3 2PF.

The Trustees who served in the year (including post year end appointments / resignations) were:

Dr David Holbrook (Chairman)
Mary Collier
Susan Eggleton
Dr Martin Giles
Kay Glendinning MBE (resigned on 25 July 2024)
Prof Clare Selden (resigned on 22 July 2025)

Prof Sir Roger Penrose OM FRS — Patron
Kay Glendinning MBE — Patron from 25 July 2024

Structure, governance and management

The Board of Management comprised of five Trustees and two Patrons during the year ended 31 December 2024. The members are able to draw on relevant board experience in board deliberations. The Board is collectively responsible for the competent management of the organisation in accordance with its objectives which are set out in the Trust Deed which is the Charity's governing document. The Board meets twice a year to monitor the organisation's strategy and activities.

If the need arose to appoint a new trustee the remaining Trustees would identify and appoint an appropriate person. The current Trustees are responsible for the induction of any new trustee which involves making them aware of the Trustees' responsibilities, the governing documents, administrative procedures and the history and philosophical approach of the Charity.

The Charity does not have any employees and its day to day activities and fundraising efforts are carried out by researchers from University College London, volunteers and trustees, under the supervision of one of the Trustees. The Trustees have agreed a position that should any profits arise from the intellectual property in the research being carried out by the team generally, and in conjunction with the various other parties involved in that work, the Charity would be entitled to a proportion of such amounts as per the Association of Medical Research Documentation (AMRC).

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

Objectives and activities

The objects of the charity are:

1. The relief of patients suffering from disease of the liver and genetic defects affecting the liver.
2. The promotion of research into the causes and treatment of diseases of the liver on terms that the results of such research are published.
3. Without prejudice to the generality of the foregoing to fund and support existing and future research into such matters at UCL Medical School (Liver Group) at the Royal Free Hospital or any other establishment into which such unit may be amalgamated and transferred in the future.

The principal activity of the Charity currently is the project being conducted to develop an artificial liver. The artificial liver project is being carried out with the funds raised for the continuing "Liver for Life" Appeal.

All the activities of the Charity were undertaken to further its purposes for the public benefit in line with the Charity's long-term objective of providing the relief of patients suffering from diseases of the liver and genetic defects affecting the liver, and promoting research into the causes and treatment of liver disease. The Charity has complied with section 17 of the Charities Act 2011 having due regard of the public benefit guidance published by the Commission.

Review of the period (including financial review)

The organisation remains funded mainly by donations. They are a mixture of individual, corporate and charitable trust donations. During the year external donations totalled £13,744 (2023: £11,454).

The majority of funds are spent on paying the cost of researchers, as well as the required consumables and equipment for the research to continue. As evidenced by the publications arising from the work, the Charity's current aim to develop a bio-artificial liver machine has moved forward from the medium scale to human scale, and now on to clinical scale, and towards readiness for a first-in-human trial.

The following period will see an advance to GMP manufacture, regulatory and ethics approval for a first in human trial. Each of these steps is associated with a considerable increase in research personnel, consumable and equipment expenditure. For 2024, expenditure totalled £35,038 (2023: £173,189). Except for such funds as the Trustees consider prudent to maintain for the purpose of management and administration of the Charity for the foreseeable future, all unrestricted funds are applied for the purposes of the 'Liver for Life' project and the general charitable objects of the Charity. The Trustees consider that £28,905 (2023: £45,971) of unrestricted reserves is more than sufficient to fund 6 months of current operations. During the period, the Charity recorded a deficit of £17,066 (2023: deficit of £154,179). The Charity's unrestricted fund is already committed to existing research.

As the bio-artificial liver project nears clinical scale and development for clinical trial, the costs are rapidly increasing necessitating considerable further fund-raising.

During 2017, the Trustees, on behalf of The Liver Group Charity CIO, entered into an agreement with Liver Health such that a proportion of any income from the sale of their drink product will be donated to The Liver Group Charity CIO. The Trustees felt that this would be a beneficial outcome for the charity if the product is successful. As well as proving a financial benefit, it would also raise awareness of the Charity itself and the risks of liver disease. This agreement is ongoing, although no funds have been received in 2023 or 2024.

**TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

Achievements and performance

- Research output, intellectual property gained from the academic group funded by The Liver Group Charity, and achievement of milestones towards moving the bioartificial liver project from the bench to the bedside. Further details are set out in the Chairman's report on page 6.
- Administrative charitable activities are limited to fundraising for the research endeavour. This is achieved by written applications to known grant giving organisations, small and large companies via the CEOs or other appropriate individual or wealthy individual donors. The Charity also has a web page with an opportunity to donate via Charities Aid Foundation. During the period from 1 January 2024 to 31 December 2024, external income of £13,744 (2023: £11,454) was raised from donations and grants; other income of £4,228 (2023: £7,556) was generated from interest earned on cash deposits.
- Indicators of achievements are success in the research aims and, in addition, the total funds raised in a particular year. These rarely exceed our expenditure for the year.
- The Charity is one of many sourcing the same research funding; given the difficult position most UK universities find themselves in, there is increasing competition for funds. Until government resources fill the gap between the costs and current funding of medical research the Charity's efforts will become more difficult each year. Notwithstanding this difficult climate, and the recent world events having a considerable negative effect on possible fundraising activities the Charity continues to explore every avenue to increase funding from grants and donations.
- The impact of the Pandemic even in 2024: The Pandemic has indeed thrown up several challenges, both direct to the Charity in terms of making fundraising a lot more difficult, since we were still unable to hold any actual in person fundraising events in areas where likely donations would be forthcoming e.g. hospital foyers etc., nor had volunteers to organise sponsorship opportunities. We continue our strategy of approaching small trusts by mail with reasonable success, and our social media pages are also a source of fundraising, however, the income in 2024 was considerably less than the expenditure in that year, and judging by the current situation will not be significantly different in 2025. This has precluded the Charity from providing a PhD studentship for any new student as the existing student finished in early 2022.
Whilst the research funded by the Charity has returned to practical endeavour in the laboratory, the opportunity to fund fewer researchers is limiting. It has, however, continued as best as possible, with much analysis, input to regulatory documentation and small scale experimental work.

Going concern

After making appropriate enquiries, the trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the Accounting Policies.

Risk management

The Trustees confirm that there are ongoing processes for identifying, evaluating and managing significant risks faced by the organisation.

Plans for future periods

The Charity aims to continue its medical research goals, at a pace commensurate with funding opportunities. With appropriate funding, it sees the bio-artificial liver machine project reach the clinical trial assessment within five years.

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' Report and the financial statement in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the Trustees and signed on their behalf by:

Martin Giles

Dr Martin Giles

(Trustee)

Date: 30 October 2025

CHAIRMAN'S STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2024

The chairman presents his statement for the Year.

Despite another difficult fundraising environment for both the charity and the research sectors it has been another year of significant progress for the project which the Charity funds via its Liver for Life Appeal. Professor Clare Selden and her team at University College London (UCL) have continued to advance the HepatiCan™ Bioartificial Liver Project.

On the technical front significant work has been done, including strengthening patents, collaborations with medical physicists on biomass warming, applying for and winning grants to further improve various aspects of the device and published papers on the cryobiological aspects of upscaling cryopreservation for encapsulated liver cell therapies. The charity provided funds for two salaried researchers up to 31st July 2024 and consumables thereafter. The team, under Professor Selden should be congratulated on this progress over the year.

Looking ahead, the charity is committed to helping the translation of liver research to the patient, and its primary and sole focus at present (as peer reviewed) is to continue to support the artificial liver project at UCL. As the project morphs from a research project to a development one, this changes the landscape of available sources of funding for the project, from academic grants and charitable donations to more commercial sources such as the venture capital and other forms of investment which seeks a financial return.

Accordingly, Professor Selden has given notice to the Charity that she now owns the intellectual property (IP) relating to the project by way of an assignment agreement with UCL and intends to commercialise HepatiCan™ through a company vehicle. Negotiations will take place at arm's length with Professor Selden to ensure that the Charity receives a fair apportionment of any commercial upside which could possibly ensue from the commercialisation of the intellectual property which the Charity – along with other bodies – has helped to fund. This could, inter alia, include the Charity receiving future payments on the eventual commercialisation of the product or on the sale of the company itself. Progress on this matter will be reported in the next Chairmans Statement.

In all of these matters the Trustees are mindful to manage any possible conflicts of interest between Professor Selden in her capacity as an academic receiving funding from the Charity, a founder of a spin-out company established to commercialise HepatiCan™ and as a Trustee of the Charity. The Trustees have, and will continue to seek, the advice of the Charity Commission on these issues and have adopted the broad Conflict of Interests policy of the British Heart Foundation as an example of best practice.

Special thanks are due to all the volunteers, fundraisers, Trustees and scientific and support staff who make this Charity possible. This year, special thanks are due to the research team of Eloy Erro, Tom Brookshaw and Sherri Chalmers and our completed apprentice Rosa French who we wish well for the future. The board of Trustees have as ever been a great help and special thanks go to Dr. Martin Giles for his work on financial and risk management matters, Mary Collier on legal issues, and Sue Eggleton for her risk management and accounting expertise.

Finally, we are sorry that after many years as a Trustee and benefactor of the Charity, we say goodbye to Kay Glendinning as a Trustee. Kay will now be a Patron of the Charity and I would like to thank her for her unstinting work and generosity with the Charity, since its inception. Her wisdom and insights will be hard to replace.

2025 will probably be my last statement as Chairman, as after 10 years as a Trustee and more latterly Chair, I feel it is only right that I make way now for someone else. It has been a real honour serving this wonderful Charity and I wish it all the very best for the future.



Dr David Holbrook
Chairman

Date: 30 October 2025

THE LIVER GROUP CHARITY CIO

STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2024

	Note	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:					
Donations and legacies	2	13,744	-	13,744	11,454
Investments	3	4,228	-	4,228	7,556
Total income		17,972	-	17,972	19,010
Expenditure on:					
Charitable activities	4	35,038	-	35,038	173,189
Total expenditure		35,038	-	35,038	173,189
Net movement in funds		(17,066)	-	(17,066)	(154,179)
Reconciliation of funds:					
Total funds brought forward		45,971	8,351	54,322	208,501
Net movement in funds		(17,066)	-	(17,066)	(154,179)
Total funds carried forward		28,905	8,351	37,256	54,322

The Statement of Financial Activities includes all gains and losses recognised in the Year.

The notes on pages 9 to 16 form part of these financial statements.

THE LIVER GROUP CHARITY CIO


BALANCE SHEET

AS AT 31 DECEMBER 2024

	Note	2024 £	2024 £	2023 £	2023 £
Current assets					
Debtors	7	508		7,002	
Cash at bank and in hand		80,450		168,606	
		<u>80,958</u>		<u>175,608</u>	
Current liabilities					
Creditors: amounts falling due within one year	8	(43,702)		(121,286)	
Net current assets			37,256		54,322
Total net assets			<u>37,256</u>		<u>54,322</u>
Charity funds					
Restricted funds	9		8,351		8,351
Unrestricted funds	9		28,905		45,971
Total funds			<u>37,256</u>		<u>54,322</u>

The figures shown in brackets above represent amounts payable by the Charity as at 31 December.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



Dr David Holbrook
Chairman

Date: 30 October 2025

The notes on pages 9 to 16 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) effective 1 January 2019 and Charities Act 2011.

The Liver Group Charity CIO meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

1.2 Going concern

The charity is mainly reliant upon donations to raise revenue to meet future expenditure. The Trustees consider that it is appropriate to prepare the financial statements on a going concern basis due to the level of reserves held. This also assumes that the charity will be successful in its fundraising activities. The financial statements do not include any adjustments that would result if insufficient funds are raised.

1.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

1.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources.

Charitable activity costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies (continued)

1.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

1.6 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered.

1.7 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.8 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation.

Trade and other creditors are recognised at the settlement amount after any trade discounts received. Accruals are value based on the estimated amount to be paid.

1.9 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.10 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.11 Donated goods and services

The Charity does not value donated services in the accounts. Services that are received, such as volunteers' time and the use of the laboratory space at University College London are either deemed not to be material or too onerous to value for a charity of this size.

THE LIVER GROUP CHARITY CIO

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

2. Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
Donations	13,744	-	13,744

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Donations	1,454	10,000	11,454

3. Investment income

	Unrestricted funds 2024 £	Total funds 2024 £
Bank Interest	4,228	4,228

	Unrestricted funds 2023 £	Total funds 2023 £
Bank Interest	7,556	7,556

4. Analysis of expenditure on charitable activities

Summary by fund type

	Unrestricted funds 2024 £	Total 2024 £
Charitable costs	35,038	35,038

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

4. Analysis of expenditure on charitable activities (continued)

Summary by fund type (continued)

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Charitable costs	161,540	11,649	173,189

5. Analysis of expenditure by activities

	Activities undertaken directly 2024 £	Support costs 2024 £	Total funds 2024 £
Charitable costs	31,112	3,926	35,038

	Activities undertaken directly 2023 £	Support costs 2023 £	Total funds 2023 £
Charitable costs	168,674	4,515	173,189

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

5. Analysis of expenditure by activities (continued)

Analysis of direct costs

	Activities 2024 £	Total funds 2024 £
Researchers (costs paid to UCL)	31,112	31,112

	Activities 2023 £	Total funds 2023 £
Patent costs	11,649	11,649
Researchers (costs paid to UCL)	157,025	157,025
	168,674	168,674

Analysis of support costs

	Activities 2024 £	Total funds 2024 £
Accountancy fee	1,500	1,500
Sundry expenses	2,216	2,216
Bank charges	210	210
	3,926	3,926

	Activities 2023 £	Total funds 2023 £
Accountancy fee	2,900	2,900
Sundry expenses	36	36
Independent examination fees (governance)	1,000	1,000
Bank charges	579	579
	4,515	4,515

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

6. Staff costs

The Charity had no employees during the period but supported the costs of researchers who are themselves employed by University College London.

The average monthly number of UCL employees supported by The Liver Group Charity CIO during the period was 2. At the period-end there were 0 employees of UCL working on The Liver Group Charity CIO funded research.

During the period, a number of volunteers gave their time to assist the Charity. No remuneration, other than travel expenses to and from the place of work, were paid to them and the Charity thanks them for their generosity.

The Trustees did not receive any remuneration, benefits in kind and reimbursement of expenses (2023: £nil).

7. Debtors

	2024 £	2023 £
Due within one year		
Other debtors	502	48
Accrued income	6	6,954
	<u>508</u>	<u>7,002</u>

8. Creditors: Amounts falling due within one year

	2024 £	2023 £
Amounts due to UCL	42,202	118,286
Accruals	1,500	3,000
	<u>43,702</u>	<u>121,286</u>

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

9. Statement of funds

Statement of funds - current Year

	Balance at 1 January 2024 £	Income £	Expenditure £	Balance at 31 December 2024 £
Unrestricted funds				
General Funds	45,971	17,972	(35,038)	28,905
Restricted funds				
Patent costs	8,351	-	-	8,351
Total of funds	54,322	17,972	(35,038)	37,256

Statement of funds - prior Year

	Balance at 1 January 2023 £	Income £	Expenditure £	Balance at 31 December 2023 £
Unrestricted funds				
General Funds	198,501	9,010	(161,540)	45,971
Restricted funds				
Patent costs	10,000	10,000	(11,649)	8,351
Total of funds	208,501	19,010	(173,189)	54,322

The restricted fund was contributed to be used to cover patent costs.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

10. Analysis of net assets between funds

Analysis of net assets between funds - current period

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total funds 2024 £
Current assets	72,607	8,351	80,958
Creditors due within one year	(43,702)	-	(43,702)
Total	28,905	8,351	37,256

Analysis of net assets between funds - prior period

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total funds 2023 £
Current assets	167,257	8,351	175,608
Creditors due within one year	(121,286)	-	(121,286)
Total	45,971	8,351	54,322

11. Related party transactions

Donations from trustees totalled £416 (2023 - £10,000) during the year.

At the year end, an amount of £68 was due from a trustee (2023 - £48).

There were no other related party transactions during the current year or prior year.

THE LIVER GROUP CHARITY CIO

DONATIONS TO THE “LIVER FOR LIFE” APPEAL

We are grateful to the following for donations to the “Liver for Life” Appeal

A Benjamin	J Davies (In memory of Jilly Davies)	The Arnold Burton 1998 Charitable Trust
A C Selden	J Gibbs	The Astor Foundation
A Davies (In memory of Jilly Davies)	Jardine Insurance Services Ltd	The Balint Family Trust
A Dowse	JM Elgie (In memory of Jilly Davies)	The Bergqvist Charitable Trust
A Gregory	J Hughes	The Bernard Sunley Charitable Foundation
A Silva	John Taylor Funeral Service	The Big Give
Amanda Ebanks	Just Text Giving	The Boots Charitable Trust
Armourers & Brasiers Gauntlet Trust	KPMG Pet Marwick	The Bowerman Memorial Trust
Associated British Ports Ltd	Laings of London	The Catherine Cookson Charitable Trust
BAE Systems	Land Securities Plc	The Chandris Foundation
Bank of England	Life Technologies	The Charles Littlewood Hill Charitable Trust
Barclays Bank (Knightsbridge Limited)	Linder Myers LLP	The Childwick Trust
Billingsgate Christian Mission Charitable Trust	L Joyce	The Clothworkers Foundation
Bryan Guinness Charitable Trust	L Provost	The Cooper Charitable Trust
BTR PLC	Lloyds Bank Plc	The Dunhill Medical Trust
C Binks	Lords Hampstead	The Economist
C Collins	Mackintosh Foundation	The Eranda Foundation
C Jones (In memory of Jilly Davies)	Mars UK Corporate Services Ltd	The Fitton Trust
C W Mills	M Cooper	The Forte Charitable Trust
CAF	M L Weinstein	The Garfield Weston Foundation
Catherine Cookson Foundation	M Matthews	The Gerald Palmer Eling Trust
CE Heath PLC	Maureen Ng (In memory of Sai Peng)	The Haberdashers Company
Chandris Foundation	Menzies Group	The Hamamelis Trust
Chapman Charitable Trust	MF Cullen (In memory of Jilly Davies)	The Hartnett Charitable Trust
Charities Trust	Misses Barrie Charitable Trust	The Hospital Saturday Fund
Citibank	N Davies	The John & Celia Bonham Christie Charitable Trust
Communis Plc	N Low	The John Ellerman Foundation
Conoco Philips	N Smith Charitable Settlement	The Lennox Hannay Charitable Trust
Cookson Group Plc	New Brunswick	The Loke Wan Tho Foundation
Courage Brewery	P Davies (In memory of Dr C Davies)	The Mary Webb Trust
Coutts Charitable Trust	Pamela Godfrey	The Michael and Anna Wix Charitable Trust
CSB Nitsch	P Smith	The Peter Bowring Charitable Trust
C Selden	Peter Stebbings Memorial Charity	The Pharsalia Charitable Trust
D Davies (In memory of Jilly Davies)	Pfizer Ltd	The Pharmaceutical Brand Consultancy
Dako Limited	PWC	The Oakdale Trust
Daunt Book	R C & Mrs D Ward	The Really Helpful Group
E C Robinson	R Mulji	The Reuben Foundation
E Wright	R F Venn (In memory of Jilly Davies)	The Roger Vere Foundation
Edgar E. Lawley Foundation	R J Price	The SMB Trust
Edwin George Robinson Charitable Trust	R Stowell	The Sobell Foundation
EJH Stephenson (Deceased) Charitable Trust	Reuben Foundation	The Steel Charitable Trust
Everyclick & GAYL	Robert Fleming Holidays Ltd	The Walter Guinness Charitable Trust
Everyman Cinemas	Robert Luff Foundation Ltd	The Worshipful Company of Saddlers
Fishmonger's Company	Roger Vere Foundation	The Worshipful Company of Salters
Friends Provident	Rowan Bentall Charitable Trust	Thomson Corporation Charitable Trust
G Davies	Royal London Insurance Ltd / Scottish Life	Thriplow Charitable Trust
Gary Ingham Hair Salon and Spa	Sandoz	TI Group
Gauchos	S Collins	Tom and Sheila Springer Charity
Generosity (by IndieGogo)	Schroders Plc	Tomkins Plc
Glaxo Plc	Seagrams Distillery Charitable Trust	Vauxhall
Guardian Royal Exchange Plc	Securicor Plc	Violet M Richards Charity
Haymills Charitable Trust	S Guglani	Wagamama
HJ Heinz Co Ltd Charitable Trust	Sir Samuel Scott of Yews Trust	Waterstones
HMRC	Smiths Group PLC	Whitbread Plc
Hon C A Pearson's Charity Trust	Snappy Snaps	Wilkinson Hardware Stores Ltd
Honeywell	Societe Generale UK	William & Mabel Morris Charitable Trust
Hudeson Charitable Trust	Stella Symons Foundation	Yorkshire and Clydesdale Bank
	Sunlife Assurance	Zara Restaurant

We would also like to thank those who have donated anonymously.

The Liver Group Charity CIO

Publications arising from the work funded by the Liver Group Charity in 2024

1. Cryobiological aspects of upscaling cryopreservation for encapsulated liver cell therapies
Tom Brookshaw , Barry Fuller , Eloy Erro, Tamnia Islam, Sweta Chandel, Elizaveta Zotova, Clare Selden, Cryobiology [Volume 117](#), December 2024, 105155
<https://doi.org/10.1016/j.cryobiol.2024.105155>
2. International Patent filed June 2024 Application reference no. J113931GB; Bioartificial Liver
3. Evaluation of a functional single-use Bioartificial Liver (BAL) biocartridge consisting of cryopreservable alginate encapsulated liver spheroids as a component of HepatiCan™, a novel Bioartificial Liver device. Frontiers in Bioengineering and Biotechnology, section Cell and Gene Therapy – submitted Jan 2025, reviewed and resubmitted May 25 (1 reviewer accepted our response awaiting second reviewer decision to have final outcome). Eloy Erro, Tom Brookshaw, Barry Fuller, Sweta Chandel, Joana Mendonca da Silva, Elizaveta Zotova, Sherri-Ann Chalmers, Alfie Watt, Clare Selden.
4. Design and In vitro testing at clinical scale of HepatiCan™, a novel bioartificial liver combined ATMP and medical device, for the treatment of Acute Liver Failure. Manuscript in preparation.